A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) (NCT04895696)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants With Active Systemic Lupus Erythematosus
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0100 — Birmingham, Alabama
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (147 Sites)
Showing the first 25 of 147 sites.
- Local Institution - 0100 — Birmingham, Alabama
- Local Institution - 0123 — Huntington Beach, California
- Local Institution - 0170 — La Jolla, California
- Local Institution - 0159 — La Palma, California
- Local Institution - 0172 — San Diego, California
- Local Institution - 0164 — Woodland Hills, California
- Local Institution - 0121 — Clearwater, Florida
- Local Institution - 0167 — Kissimmee, Florida
- Local Institution - 0122 — Orlando, Florida
- Local Institution - 0173 — Ormond Beach, Florida
- Local Institution - 0154 — Plantation, Florida
- Local Institution - 0137 — South Miami, Florida
- Local Institution - 0155 — Tamarac, Florida
- Local Institution - 0160 — Atlanta, Georgia
- Local Institution - 0205 — Suwanee, Georgia
- Local Institution - 0146 — Orland Park, Illinois
- Local Institution - 0187 — Hopkinsville, Kentucky
- Local Institution - 0171 — Baton Rouge, Louisiana
- Local Institution - 0134 — Wheaton, Maryland
- Local Institution - 0070 — Eagan, Minnesota
- Local Institution - 0124 — St Louis, Missouri
- Local Institution - 0165 — St Louis, Missouri
- Local Institution - 0091 — Las Vegas, Nevada
- Local Institution - 0219 — West Long Branch, New Jersey
- Local Institution - 0140 — Manhasset, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice — Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.